Insulin treatment in children and adolescents with diabetes

Pediatric Diabetes

Volumn 15, Issue SUPPL.20, 2014, Pages 115-134

  Danne, Thomas ^a   Bangstad, Hans Jacob ^b   Deeb, Larry ^c   Jarosz Chobot, Przemyslawa ^d   Mungaie, Lucy ^e   Saboo, Banshi ^f   Urakami, Tatsuhiko ^g   Battelino, Tadej ^h,i   Hanas, Ragnar ^j  

^a Kinder und Jugendlkrankenhaus AUF DER BULT   (Germany)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f Department of Research   (India)

^g NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

ⁱ UNIVERSITY OF LJUBLJANA   (Slovenia)

^j UNIVERSITY OF GOTHENBURG   (Sweden)

more..

Author keywords

Children; Diabetes; Guidelines; Insulin

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ADOLESCENT; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; CHILD; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFANT; INSULIN INFUSION; INTERNATIONAL COOPERATION; MEDICINE; MULTIMODALITY CANCER THERAPY; PEDIATRICS; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRESCHOOL CHILD; SUBCUTANEOUS DRUG ADMINISTRATION; TRENDS;

ADOLESCENT; ADOLESCENT MEDICINE; CHILD; CHILD, PRESCHOOL; CIRCADIAN RHYTHM; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG MONITORING; EVIDENCE-BASED MEDICINE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; INFANT; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; INTERNATIONAL AGENCIES; PEDIATRICS; SOCIETIES, SCIENTIFIC;

EID: 84906842234     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12184     Document Type: Article

References (184)

1. Bangstad HJ, Danne T, Deeb L, Jarosz-Chobot P, Urakami T, Hanas R. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes 2009: 10 (Suppl. 12): 82-99.
2. Johnsson S. Retinopathy and nephropathy in diabetes mellitus: comparison of the effects of two forms of treatment. Diabetes 1960: 9: 1-8.
3. Siebenhofer A, Plank J, Berghold A et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006: CD003287.
4. Brunner GA, Hirschberger S, Sendlhofer G et al. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 2000: 17: 371-375.
5. Danne T, Deiss D, Hopfenmuller W, von Schutz W, Kordonouri O. Experience with insulin analogues in children. Horm Res 2002: 57 (Suppl. 1): 46-53.
6. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000: 159: 483-488.
7. Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005: 28: 2100-2105.
8. Acerini CL, Cheetham TD, Edge JA, Dunger DB. Both insulin sensitivity and insulin clearance in children and young adults with type I (insulin-dependent) diabetes vary with growth hormone concentrations and with age. Diabetologia 2000: 43: 61-68.
9. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986: 315: 215-219.
10. Plank J, Wutte A, Brunner G et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002: 25: 2053-2057.
11. Cemeroglu AP, Kleis L, Wood A, Parkes C, Wood MA, Davis AT. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 DM on multiple daily injections. Endocr Pract 2013: 2013; 19:614-619.
12. Heise T, Nosek L, Spitzer H et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007: 9: 746-753.
13. Ford-Adams ME, Murphy NP, Moore EJ et al. Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med 2003: 20: 656-660.
14. Deeb LC, Holcombe JH, Brunelle R et al. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics 2001: 108: 1175-1179.
15. Tubiana-Rufi N, Coutant R, Bloch J et al. Special management of insulin lispro in continuous subcutaneous insulin infusion in young diabetic children: a randomized cross-over study. Horm Res 2004: 62: 265-271.
16. Tupola S, Komulainen J, Jaaskelainen J, Sipila I. Post-prandial insulin lispro vs. human regular insulin in prepubertal children with type 1 diabetes mellitus. Diabet Med 2001: 18: 654-658.
17. Holcombe JH, Zalani S, Arora VK, Mast CJ. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002: 24: 629-638.
18. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 1999: 22: 784-788.
19. Rutledge KS, Chase HP, Klingensmith GJ, Walravens PA, Slover RH, Garg SK. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 1997: 100: 968-972.
20. Heller SR, Colagiuri S, Vaaler S et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004: 21: 769-775.
21. Home PD, Lindholm A, Riis A, European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000: 17: 762-770.
22. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004: 53: 1614-1620.
23. Danne T, Datz N, Endahl L et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes 2008: 9: 554-560.
24. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004: 47: 622-629.
25. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care 2001: 24: 2005-2006.
26. Debrah K, Sherwin RS, Murphy J, Kerr D. Effect of caffeine on recognition of and physiological responses to hypoglycaemia in insulin-dependent diabetes. Lancet 1996: 347: 19-24.
27. Porcellati F, Rossetti P, Pampanelli S et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004: 21: 1213-1220.
28. NICE. (National Institute of Clinical Excellence). Guidance on the Use of Long-Acting Insulin Analogues for the Treatment of Diabetes-Insulin Glargine. Technology Appraisal Guidance No 53 2002 (available from http://guidance.nice.org.uk/TA53/guidance/pdf/English).
29. Chase HP, Dixon B, Pearson J et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 2003: 143: 737-740.
30. Hathout EH, Fujishige L, Geach J, Ischandar M, Maruo S, Mace JW. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther 2003: 5: 801-806.
31. Alemzadeh R, Berhe T, Wyatt DT. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics 2005: 115: 1320-1324.
32. Mohn A, Strang S, Wernicke-Panten K, Lang AM, Edge JA, Dunger DB. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 2000: 23: 557-559.
33. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007: 24: 27-34.
34. Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003: 26: 3087-3092.
35. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003: 26: 590-596.
36. de Beaufort CE, Houtzagers CM, Bruining GJ et al. Continuous subcutaneous insulin infusion (CSII) versus conventional injection therapy in newly diagnosed diabetic children: two-year follow- up of a randomized, prospective trial. Diabet Med 1989: 6: 766-771.
37. DCCT. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr 1994: 125: 177-188.
38. Jacobson AM, Musen G, Ryan CM et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007: 356: 1842-1852.
39. Musen G, Jacobson AM, Ryan CM et al. Impact of diabetes and its treatment on cognitive function among adolescents who participated in the Diabetes Control and Complications Trial. Diabetes Care 2008: 31: 1933-1938.
40. Mortensen HB, Robertson KJ, Aanstoot HJ et al. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidore Study Group on Childhood Diabetes. Diabet Med 1998: 15: 752-759.
41. Downie E, Craig ME, Hing S, Cusumano J, Chan AK, Donaghue KC. Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control. Diabetes Care 2011: 34: 2368-2373.
42. DiMeglio LA, Pottorff TM, Boyd SR, France L, Fineberg N, Eugster EA. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr 2004: 145: 380-384.
43. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002: 324: 705.
44. Willi SM, Planton J, Egede L, Schwarz S. Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr 2003: 143: 796-801.
45. Kaufman FR. Intensive management of type 1 diabetes in young children. Lancet 2005: 365: 737-738.
46. Hanas R, Adolfsson P. Insulin pumps in pediatric routine care improve long-term metabolic control without increasing the risk of hypoglycemia. Pediatr Diabetes 2006: 7: 25-31.
47. Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes. Diabetes Care 1999: 22: 1779-1784.
48. Litton J, Rice A, Friedman N, Oden J, Lee MM, Freemark M. Insulin pump therapy in toddlers and preschool children with type 1 diabetes mellitus. J Pediatr 2002: 141: 490-495.
49. Ahern JAH, Boland EA, Doane R et al. Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups. Pediatr Diabetes 2002: 3: 10-15.
50. Plotnick LP, Clark LM, Brancati FL, Erlinger T. Safety and effectiveness of insulin pump therapy in children and adolescents with type 1 diabetes. Diabetes Care 2003: 26: 1142-1146.
51. Saha ME, Huuppone T, Mikael K, Juuti M, Komulainen J. Continuous subcutaneous insulin infusion in the treatment of children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002: 15: 1005-1010.
52. Sulli N, Shashaj B. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia. J Pediatr Endocrinol Metab 2003: 16: 393-399.
53. Skogsberg L, Fors H, Hanas R, Chaplin JE, Lindman E, Skogsberg J. Improved treatment satisfaction but no difference in metabolic control when using continuous subcutaneous insulin infusion vs. multiple daily injections in children at onset of type 1 diabetes mellitus. Pediatr Diabetes 2008: 9: 472-479.
54. Bolli GB, Kerr D, Thomas R et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009: 32: 1170-1176.
55. Colquitt J, Royle P, Waugh N. Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta-analysis. Diabet Med 2003: 20: 863-866.
56. Sulmont V, Souchon PF, Gouillard-Darnaud C et al. Metabolic control in children with diabetes mellitus who are younger than 6 years at diagnosis: continuous subcutaneous insulin infusion as a first line treatment? J Pediatr 2010: 157: 103-107.
57. Danne T, Battelino T, Jarosz-Chobot P et al. Establishing glycaemic control with continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: experience of the PedPump Study in 17 countries. Diabetologia 2008: 51: 1594-1601.
58. Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007: 30: 1653-1662.
59. Pankowska E, Blazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes 2009: 10: 52-58.
60. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993: 329: 977-986.
61. White NH, Cleary PA, Dahms W, Goldstein D, Malone J, Tamborlane WV. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001: 139: 804-812.
62. Battelino T, Conget I, Olsen B et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012: 55: 3155-3162.
63. Elleri D, Allen JM, Kumareswaran K et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care 2013: 36: 838-844.
64. Phillip M, Battelino T, Atlas E et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013: 368: 824-833.
65. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008: 31: 934-939.
66. Lauritzen T. Pharmacokinetic and clinical aspects of intensified subcutaneous insulin therapy. Dan Med Bull 1985: 32: 104-118.
67. Becker R, Frick A, Heinemann L, Nosek L, Rave K. Dose response relation of insulin glulisine (GLU) in subjects with type 1 diabetes (T1DM). Diabetes 2005: 54 (Suppl. 1): Abstract 1367-P.
68. Woodworth J, Howey D, Bowsher R, Lutz S, Sanat P, Brady P. Lys(B28), Pro(B29) human insulin (K): dose ranging vs. humulin R (H). Diabetologia 1993: 42 (Suppl. 1): 54A.
69. Nosek L, Heinemann L, Kaiser M, Arnolds S, Heise T. No increase in the duration of action with rising doses of insulin aspart. Diabetes 2003: 52 (Suppl. 1): Abstract 551-P.
70. Philotheou A, Arslanian S, Blatniczky L, Peterkova V, Souhami E, Danne T. Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes. Diabetes Technol Ther 2011: 13: 327-334.
71. Danne T, Aman J, Schober E et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003: 26: 2359-2364.
72. Krasner A, Pohl R, Simms P, Pichotta P, Hauser R, De Souza E. A review of a family of ultra-rapid-acting insulins: formulation development. J Diabetes Sci Technol 2012: 6: 786-796.
73. Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000: 49: 999-1005.
74. European Medicines Agency (EMA) Statement 2013 (available from http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2013/05/WC500143823.pdf).
75. Stiller R, Kothny T, Gudat U et al. Intravenous administration of insulin lispro versus regular insulin in patients with type 1 diabetes. Diabetes 1999: 48 (Suppl. 1): Abstract 0497.
76. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000: 49: 2142-2148.
77. Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther 2009: 31: 2086-2097.
78. Dixon B, Peter Chase H, Burdick J et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes 2005: 6: 150-154.
79. Thisted H, Johnsen SP, Rungby J. An update on the long-acting insulin analogue glargine. Basic Clin Pharmacol Toxicol 2006: 99: 1-11.
80. Päivärinta M, Tapanainen P, Veijola R. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes 2008: 9: 83-90.
81. Danne T, Philotheou A, Goldman D et al. A randomized trial comparing the rate of hypoglycemia - assessed using continuous glucose monitoring - in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Pediatr Diabetes 2013: 14: 593-601.
82. Hamann A, Matthaei S, Rosak C, Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003: 26: 1738-1744.
83. Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L. No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes. Diabet Med 2002: 19: 490-495.
84. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000: 23: 639-643.
85. Plank J, Bodenlenz M, Sinner F et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005: 28: 1107-1112.
86. Carlsson A, Forsander G, Ludvigsson J, Larsen S, Ortqvist E, Group SP-YS. A multicenter observational safety study in Swedish children and adolescents using insulin detemir for the treatment of type 1 diabetes. Pediatr Diabetes 2013: 14: 358-365.
87. Biester T, Blaesig S, Remus K et al. Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Pediatr Diabetes 2014: 15: 27-33.
88. Rosenstock J, Bergenstal RM, Blevins TC et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care 2013: 36: 522-528.
89. Mortensen H, Kocova M, Teng LY, Keiding J, Bruckner I, Philotheou A. Biphasic insulin aspart vs. human insulin in adolescents with type 1 diabetes on multiple daily insulin injections. Pediatr Diabetes 2006: 7: 4-10.
90. Stickelmeyer MP, Graf CJ, Frank BH, Ballard RL, Storms SM. Stability of U-10 and U-50 dilutions of insulin lispro. Diabetes Technol Ther 2000: 2: 61-66.
91. Jorgensen D, Solbeck H. Dilution of insulin aspart with NPH medium for small dose use in continuous subcutaneous insulin infusion does not affect in vitro stability. Diabetes 2005: 54 (Suppl. 1): Abstract A102.
92. Datz N, Westergaard L, Nestoris C et al. Increase of insulin requirements after changing from U40 to U100 insulin in children and adolescents with type 1 diabetes without effect on the metabolic status. Pediatr Diabetes 2008: 9: Abstract 59.
93. Grajower MM, Fraser CG, Holcombe JH et al. How long should insulin be used once a vial is started? Diabetes Care 2003: 26: 2665-2666 discussion 266-9.
94. Rangawala S, Shah P, Hussain S, Goenka S, Pillai K. Insulin stored in matka (earthen pitcher) with water for 60 days does not reduce in bio-activity. J Pediatr Endocrinol Metab 1997: 10 (Suppl. 2): Abstract 347.
95. McCarthy JA, Covarrubias B, Sink P. Is the traditional alcohol wipe necessary before an insulin injection? Dogma disputed. Diabetes Care 1993: 16: 402.
96. Loeb JA, Herold KC, Barton KP, Robinson LE, Jaspan JB. Systematic approach to diagnosis and management of biphasic insulin allergy with local anti-inflammatory agents. Diabetes Care 1989: 12: 421-423.
97. Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in young patients with type 1 diabetes. Diabetes Care 2002: 25: 634.
98. Holstein A, Stege H, Kovacs P. Lipoatrophy associated with the use of insulin analogues: a new case associated with the use of insulin glargine and review of the literature. Expert Opin Drug Saf 2010: 9: 225-231.
99. Forsander GA, Malmodin OC, Kordonuri O, Ludvigsson J, Klingensmith G, Beaufort CD. An ISPAD survey insulin-induced lipoatrophy. Pediatr Diabetes 2013: 14: 1.
100. Schnell K, Biester T, Tsioli C, Datz N, Danne T, Kordonuri O. Lipoatrophy in a large pediatric diabetes outpatient service. Pediatr Diabetes 2013: 14: 20.
101. Chantelau E, Lee DM, Hemmann DM, Zipfel U, Echterhoff S. What makes insulin injections painful? BMJ 1991: 303: 26-27.
102. Hanas R, Adolfsson P, Elfvin-Akesson K et al. Indwelling catheters used from the onset of diabetes decrease injection pain and pre-injection anxiety. J Pediatr 2002: 140: 315-320.
103. Arendt-Nielsen L, Egekvist H, Bjerring P. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res 2006: 23: 37-43.
104. Ginsberg BH, Parkes JL, Sparacino C. The kinetics of insulin administration by insulin pens. Horm Metab Res 1994: 26: 584-587.
105. Sindelka G, Heinemann L, Berger M, Frenck W, Chantelau E. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia 1994: 37: 377-380.
106. Young RJ, Hannan WJ, Frier BM, Steel JM, Duncan LJ. Diabetic lipohypertrophy delays insulin absorption. Diabetes Care 1984: 7: 479-480.
107. Johansson UB, Amsberg S, Hannerz L et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care 2005: 28: 2025-2027.
108. Bantle JP, Neal L, Frankamp LM. Effects of the anatomical region used for insulin injections on glycemia in type I diabetes subjects. Diabetes Care 1993: 16: 1592-1597.
109. Frid A, Gunnarsson R, Guntner P, Linde B. Effects of accidental intramuscular injection on insulin absorption in IDDM. Diabetes Care 1988: 11: 41-45.
110. Frid A, Ostman J, Linde B. Hypoglycemia risk during exercise after intramuscular injection of insulin in thigh in IDDM. Diabetes Care 1990: 13: 473-477.
111. Frid A. Injection and absorption of insulin. PhD Thesis: Faculty of Medicine, Karolinska Institute, Stockholm, Sweden; 1992.
112. Mudaliar SR, Lindberg FA, Joyce M et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999: 22: 1501-1506.
113. ter Braak EW, Woodworth JR, Bianchi R et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care 1996: 19: 1437-1440.
114. Rave K, Heise T, Weyer C et al. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects. Diabet Med 1998: 15: 747-751.
115. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000: 23: 813-819.
116. Peter R, Luzio SD, Dunseath G et al. Effects of exercise on the absorption of insulin glargine in patients with type 1 diabetes. Diabetes Care 2005: 28: 560-565.
117. Karges B, Boehm BO, Karges W. Early hypoglycaemia after accidental intramuscular injection of insulin glargine. Diabet Med 2005: 22: 1444-1445.
118. Morrow L, Muchmore DB, Hompesch M, Ludington EA, Vaughn DE. Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabetes Care 2013: 36: 273-275.
119. Cengiz E, Weinzimer SA, Sherr JL et al. Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming. Diabetes Technol Ther 2014: 16: 20-25.
120. Schuler G, Pelz K, Kerp L. Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications? Diabetes Res Clin Pract 1992: 16: 209-212.
121. Frid A, Hirsch L, Gaspar R et al. New injection recommendations for patients with diabetes. Diabetes Metab 2010: 36 (Suppl. 2): S3-S18.
122. Hofman PL, Lawton SA, Peart JM et al. An angled insertion technique using 6-mm needles markedly reduces the risk of intramuscular injections in children and adolescents. Diabet Med 2007: 24: 1400-1405.
123. Birkebaek NH, Johansen A, Solvig J. Cutis/subcutis thickness at insulin injection sites and localization of simulated insulin boluses in children with type 1 diabetes mellitus: need for individualization of injection technique? Diabet Med 1998: 15: 965-971.
124. Smith CP, Sargent MA, Wilson BP, Price DA. Subcutaneous or intramuscular insulin injections. Arch Dis Child 1991: 66: 879-882.
125. Hanas SR, Ludvigsson J. Metabolic control is not altered when using indwelling catheters for insulin injections. Diabetes Care 1994: 17: 716-718.
126. Burdick P, Cooper S, Horner B, Cobry E, McFann K, Chase HP. Use of a subcutaneous injection port to improve glycemic control in children with type 1 diabetes. Pediatr Diabetes 2009: 10: 116-119.
127. Hanas SR, Carlsson S, Frid A, Ludvigsson J. Unchanged insulin absorption after 4 days' use of subcutaneous indwelling catheters for insulin injections. Diabetes Care 1997: 20: 487-490.
128. Hanas R, Ludvigsson J. Side effects and indwelling times of subcutaneous catheters for insulin injections: a new device for injecting insulin with a minimum of pain in the treatment of insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1990: 10: 73-83.
129. Diglas J, Feinböck C, Winkler F et al. Reduced pain perception with an automatic injection device for use with an insulin pen. Horm Res 1998: 50: Abstract A30.
130. Chiasson JL, Ducros F, Poliquin-Hamet M, Lopez D, Lecavalier L, Hamet P. Continuous subcutaneous insulin infusion (Mill-Hill Infuser) versus multiple injections (Medi-Jector) in the treatment of insulin-dependent diabetes mellitus and the effect of metabolic control on microangiopathy. Diabetes Care 1984: 7: 331-337.
131. Houtzagers CM, Visser AP, Berntzen PA, Heine RJ, van der Veen EA. The Medi-Jector II: efficacy and acceptability in insulin-dependent diabetic patients with and without needle phobia. Diabet Med 1988: 5: 135-138.
132. Engwerda EE, Abbink EJ, Tack CJ, de Galan BE. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care 2011: 34: 1804-1808.
133. Berghaeuser MA, Kapellen T, Heidtmann B, Haberland H, Klinkert C, Holl RW. Continuous subcutaneous insulin infusion in toddlers starting at diagnosis of type 1 diabetes mellitus. A multicenter analysis of 104 patients from 63 centres in Germany and Austria. Pediatr Diabetes 2008: 9: 590-595.
134. Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 2005: 28: 15-19.
135. Blackett PR. Insulin pump treatment for recurrent ketoacidosis in adolescence [letter]. Diabetes Care 1995: 18: 881-882.
136. Steindel BS, Roe TR, Costin G, Carlson M, Kaufman FR. Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus. Diabetes Res Clin Pract 1995: 27: 199-204.
137. Kapellen TM, Heidtmann B, Bachmann J, Ziegler R, Grabert M, Holl RW. Indications for insulin pump therapy in different age groups: an analysis of 1, 567 children and adolescents. Diabet Med 2007: 24: 836-842.
138. NICE. (National Institute of Clinical Excellence). Clinical and Cost Effectiveness of Continuous Subcutaneous Insulin Infusion for Diabetes. Technology Appraisal No 57 2003 (available from http://www.nice.org.uk/guidance/TA57).
139. Nahata L. Insulin therapy in pediatric patients with type I diabetes: continuous subcutaneous insulin infusion versus multiple daily injections. Clin Pediatr (Phila) 2006: 45: 503-508.
140. Skogsberg L, Lindman E, Fors H. To compare metabolic control and quality of life (QoL) of CSII with multiple daily injections (MDI) in children/adolescents at onset of T1DM. Pediatr Diabetes 2006: 7: Abstract 65.
141. Kordonouri O, Pankowska E, Rami B et al. Sensor-augmented pump therapy from the diagnosis of childhood type 1 diabetes: results of the Paediatric Onset Study (ONSET) after 12 months of treatment. Diabetologia 2010: 53: 2487-2495.
142. Enander R, Gundevall C, Stromgren A, Chaplin J, Hanas R. Carbohydrate counting with a bolus calculator improves post-prandial blood glucose levels in children and adolescents with type 1 diabetes using insulin pumps. Pediatr Diabetes 2012: 13: 545-551.
143. Zisser H, Robinson L, Bevier W et al. Bolus calculator: a review of four "smart" insulin pumps. Diabetes Technol Ther 2008: 10: 441-444.
144. Hanas R, Lundqvist K, Windell L. Blood glucose and beta-hydroxybutyrate responses when the insulin pump is stopped in children and adolescents. Pediatr Diabetes 2006: 7 (Suppl. 5): Abstract 35.
145. Zisser H. Quantifying the impact of a short-interval interruption of insulin-pump infusion sets on glycemic excursions. Diabetes Care 2008: 31: 238-239.
146. Sulli N, Shashaj B. Long-term benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes: a 4-year follow-up. Diabet Med 2006: 23: 900-906.
147. Johnson SR, Cooper MN, Jones TW, Davis EA. Long-term outcome of insulin pump therapy in children with type 1 diabetes assessed in a large population-based case-control study. Diabetologia 2013: 56: 2392-2400.
148. Hanas R, Ludvigsson J. Hypoglycemia and ketoacidosis with insulin pump therapy in children and adolescents. Pediatr Diabetes 2006: 7 (Suppl. 4): 32-38.
149. Margeirsdottir H, Larsen J, Brunborg C, Dahl-Jorgensen K. Nationwide improvement in HbA1c and complication screening in a benchmarking project in childhood diabetes. Pediatr Diabetes 2006: 7 (Suppl. 5): Abstract 18.
150. Hanas R, Lindgren F, Lindblad B. A 2-yr national population study of pediatric ketoacidosis in Sweden: predisposing conditions and insulin pump use. Pediatr Diabetes 2009: 10: 33-37.
151. Liu D, Moberg E, Wredling R, Lins PE, Adamson U. Insulin absorption is faster when keeping the infusion site in use for three days during continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 1991: 12: 19-24.
152. Bode B, Weinstein R, Bell D et al. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes. Diabetes Care 2002: 25: 439-444.
153. van Bon AC, Bode BW, Sert-Langeron C, DeVries JH, Charpentier G. Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. Diabetes Technol Ther 2011: 13: 607-614.
154. Wood JR, Moreland EC, Volkening LK, Svoren BM, Butler DA, Laffel LM. Durability of insulin pump use in pediatric patients with type 1 diabetes. Diabetes Care 2006: 29: 2355-2360.
155. Tamborlane WV, Beck RW, Bode BW et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008: 359: 1464-1476.
156. Weinzimer S, Xing D, Tansey M et al. FreeStyle navigator continuous glucose monitoring system use in children with type 1 diabetes using glargine-based multiple daily dose regimens: results of a pilot trial Diabetes Research in Children Network (DirecNet) Study Group. Diabetes Care 2008: 31: 525-527.
157. Hirsch IB, Abelseth J, Bode BW et al. Sensor-augmented insulin pump therapy: results of the first randomized treat-to-target study. Diabetes Technol Ther 2008: 10: 377-383.
158. Peyrot M, Rubin RR, Group SS. Treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial. Diabet Med 2013: 30: 464-467.
159. Slover RH, Welsh JB, Criego A et al. Effectiveness of sensor-augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study. Pediatr Diabetes 2012: 13: 6-11.
160. Buse JB, Kudva YC, Battelino T, Davis SN, Shin J, Welsh JB. Effects of sensor-augmented pump therapy on glycemic variability in well-controlled type 1 diabetes in the STAR 3 study. Diabetes Technol Ther 2012: 14: 644-647.
161. Buckingham B, Cobry E, Clinton P et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther 2009: 11: 93-97.
162. Elleri D, Allen JM, Nodale M et al. Automated overnight closed-loop glucose control in young children with type 1 diabetes. Diabetes Technol Ther 2011: 13: 419-424.
163. Nimri R, Muller I, Atlas E et al. Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis. Pediatr Diabetes 2014: 15: 91-99.
164. Hovorka R, Elleri D, Thabit H et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 2014: 37: 1204-1211.
165. Wysocki T, Harris MA, Mauras N et al. Absence of adverse effects of severe hypoglycemia on cognitive function in school-aged children with diabetes over 18 months. Diabetes Care 2003: 26: 1100-1105.
166. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens [see comments]. Lancet 1999: 354: 1604-1607.
167. Heine RJ, Bilo HJ, Fonk T, van der Veen EA, van der Meer J. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins. Diabetologia 1984: 27: 558-562.
168. Perriello G, Torlone E, Di Santo S et al. Effect of storage temperature of insulin on pharmacokinetics and pharmacodynamics of insulin mixtures injected subcutaneously in subjects with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1988: 31: 811-815.
169. Halberg I, Jacobsen L, Dahl U. A study on self-mixing insulin aspart with NPH insulin in the syringe before injection. Diabetes 1999: 48 (Suppl. 1): Abstract 448.
170. Joseph SE, Korzon-Burakowska A, Woodworth JR et al. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin. Diabetes Care 1998: 21: 2098-2102.
171. Bastyr EJ III, Holcombe JH, Anderson JH, Clore JN. Mixing insulin lispro and ultralente insulin. Diabetes Care 1997: 20: 1047-1048.
172. Kaplan W, Rodriguez LM, Smith OE, Haymond MW, Heptulla RA. Effects of mixing glargine and short-acting insulin analogs on glucose control. Diabetes Care 2004: 27: 2739-2740.
173. Fiallo-Scharer R, Horner B, McFann K, Walravens P, Chase HP. Mixing rapid-acting insulin analogues with insulin glargine in children with type 1 diabetes mellitus. J Pediatr 2006: 148: 481-484.
174. Pankowska E, Blazik M, Groele L. Does the fat-protein meal increase postprandial glucose level in type 1 diabetes patients on insulin pump: the conclusion of a randomized study. Diabetes Technol Ther 2012: 14: 16-22.
175. Cobry E, McFann K, Messer L et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther 2010: 12: 173-177.
176. Luijf YM, van Bon AC, Hoekstra JB, Devries JH. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 2010: 33: 2152-2155.
177. Weinzimer S, Xing D, Tansey M et al. Prolonged use of continuous glucose monitors in children with type 1 diabetes on continuous subcutaneous insulin infusion or intensive multiple-daily injection therapy. Pediatr Diabetes 2009: 10: 91-96.
178. Tan CY, Wilson DM, Buckingham B. Initiation of insulin glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes 2004: 5: 80-86.
179. O'Connell MA, Gilbertson HR, Donath SM, Cameron FJ. Optimizing postprandial glycemia in pediatric patients with type 1 diabetes using insulin pump therapy: impact of glycemic index and prandial bolus type. Diabetes Care 2008: 31: 1491-1495.
180. Davidson PC, Hebblewhite HR, Steed RD, Bode BW. Analysis of guidelines for basal-bolus insulin dosing: basal insulin, correction factor, and carbohydrate-to-insulin ratio. Endocr Pract 2008: 14: 1095-1101.
181. Conrad SC, McGrath MT, Gitelman SE. Transition from multiple daily injections to continuous subcutaneous insulin infusion in type 1 diabetes mellitus. J Pediatr 2002: 140: 235-240.
182. Nicolajsen T, Samuelsson A, Hanas R. Insulin doses before and one year after pump start: children have a reversed dawn phenomenon. J Diabetes Sci Technol 2012: 6: 589-594.
183. Szypowska A, Lipka M, Blazik M, Groele L, Pankowska E. Insulin requirement in preschoolers treated with insulin pumps at the onset of type 1 diabetes mellitus. Acta Paediatr 2009: 98: 527-530.
184. Ludvigsson J, Hanas R. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics 2003: 111: 933-938.